Assertio Bundle
Who Really Controls Assertio Holdings, Inc.?
Understanding the ownership structure of Assertio Holdings, Inc., formerly known as Assertio Therapeutics, is crucial for anyone tracking its strategic moves. The company's evolution, especially after the merger with Zyla Life Sciences, has reshaped its landscape. Unraveling "who owns Assertio" provides critical insights into its future direction and the interests driving its decisions.
Assertio Holdings, a specialty pharmaceutical company, operates with a market capitalization of approximately $59.1 million as of June 12, 2025, and is listed on Nasdaq under the ticker ASRT. This analysis will explore the stakes held by Assertio SWOT Analysis, institutional investors, and individual insiders, revealing how these ownership dynamics influence the company's journey. Knowing who owns Assertio is key to understanding Assertio stock performance and the future of Assertio pharmaceuticals.
Who Founded Assertio?
The history of Assertio Holdings, Inc. begins with Depomed, Inc., established in 1995. The company later rebranded to Assertio Therapeutics, Inc. in May 2020 before its current form as Assertio Holdings, Inc. This evolution involved a corporate reorganization and a merger with Zyla Life Sciences.
While detailed information about the original founders of Depomed and their initial equity distribution isn't readily available in recent public records, the company's initial public offering (IPO) on November 5, 1997, marked a significant transition to public ownership. Early-stage pharmaceutical companies often allocate substantial equity to founders and early investors.
These initial agreements frequently include vesting schedules to ensure the founders' commitment. They may also contain buy-sell clauses to manage ownership changes. Any early ownership disputes or buyouts would have influenced the distribution of control, reflecting the founding team's vision for developing and marketing pharmaceutical products.
Early Ownership Structure
Early ownership structures in the pharmaceutical industry typically involve significant stakes for founders and initial investors. These investors, such as angel investors or venture capital firms, provide the essential capital for research and development. Understanding the early ownership of companies like Assertio Therapeutics is crucial for investors. You can learn more about the company's financial strategies in the article Revenue Streams & Business Model of Assertio.
- Founders often hold a considerable portion of the initial equity.
- Early investors receive equity in exchange for funding research and development.
- Vesting schedules are common to ensure the long-term commitment of founders and key personnel.
- Buy-sell agreements can be in place to manage ownership transitions.
Assertio SWOT Analysis
- Complete SWOT Breakdown
- Fully Customizable
- Editable in Excel & Word
- Professional Formatting
- Investor-Ready Format
How Has Assertio’s Ownership Changed Over Time?
The ownership structure of Assertio Therapeutics has evolved significantly since its initial public offering (IPO) in November 1997. Understanding the shifts in ownership is crucial for investors and stakeholders. As of June 6, 2025, the company, trading under the ticker ASRT, has a substantial institutional presence, with 96 institutional owners and shareholders. These institutions collectively hold approximately 27.56% of the outstanding shares, demonstrating a notable level of institutional investor confidence.
The evolution of Assertio's ownership structure reflects its growth and strategic direction over time. The presence of major institutional investors, such as Nantahala Capital Management, LLC, The Vanguard Group, and BlackRock, indicates a level of market recognition and investor interest. These entities often play a critical role in shaping company strategy and governance through their voting power and engagement with management. For a deeper dive into the company's past, consider reading the Brief History of Assertio.
| Shareholder | Shares Held (as of March 31, 2025) | Percentage of Ownership |
|---|---|---|
| Nantahala Capital Management, LLC | 8,439,762 | 8.81% |
| Vanguard Group Inc. | 4,384,211 | Data not available |
| BlackRock, Inc. | Data not available | Data not available |
As of May 30, 2025, insider ownership, which includes shares held by company executives and directors, accounts for 7.92%. This level of insider ownership provides insight into the alignment of interests between company leadership and shareholders. The institutional ownership, which was 29.62% as of March 5, 2025, and insider holdings together provide a comprehensive view of the company's ownership landscape.
Key Takeaways on Assertio Ownership
The ownership of Assertio Therapeutics is a mix of institutional and insider holdings.
- Institutional investors hold a significant portion of the shares.
- Insider ownership shows the alignment of interests.
- Understanding ownership helps in assessing company strategy and governance.
- The information is current as of June 2025.
Assertio PESTLE Analysis
- Covers All 6 PESTLE Categories
- No Research Needed – Save Hours of Work
- Built by Experts, Trusted by Consultants
- Instant Download, Ready to Use
- 100% Editable, Fully Customizable
Who Sits on Assertio’s Board?
The current board of directors of Assertio Holdings, Inc. is pivotal in guiding the company's strategy and governance. Recent updates highlight changes, such as Mark Reisenauer's appointment to the Board of Directors on December 17, 2024, and Peter Staple's retirement around November 2024 after over two decades as an independent director. Information on the complete board composition and the representation of major shareholders is typically found in the company's annual proxy statements.
The composition of the board and its influence are vital for understanding Assertio's competitors and its strategic direction. The board's decisions directly impact the company's performance, making it crucial for investors and stakeholders to stay informed about its members and their roles.
| Board Member | Role | Date of Appointment/Change |
|---|---|---|
| Mark Reisenauer | Director | December 17, 2024 |
| Peter Staple | Former Director | Retired around November 2024 |
| Information on other board members | Details in company's proxy statements | Annually Updated |
Assertio's voting structure generally operates on a one-share-one-vote basis. As of March 5, 2025, institutional ownership stood at 29.62%, and insider ownership was 2.71%. By May 30, 2025, insider ownership increased to 7.92%, while institutional ownership decreased slightly to 29.04%. Major institutional holders like Nantahala Capital Management, LLC, Vanguard Group Inc., and BlackRock, Inc. wield considerable influence due to their substantial shareholdings. The company actively engages with investors through earnings calls and presentations, providing stakeholders with insights into its strategy and governance.
Understanding Assertio's Ownership
Understanding who owns Assertio is crucial for investors looking at Assertio stock. The board of directors plays a key role in governance, often reflecting the interests of major shareholders. The voting power is typically one share, one vote.
- Institutional ownership influences decision-making.
- Insider ownership percentages are also important.
- Regular investor engagement is a key.
- Stay updated with Assertio Therapeutics news and updates.
Assertio Business Model Canvas
- Complete 9-Block Business Model Canvas
- Effortlessly Communicate Your Business Strategy
- Investor-Ready BMC Format
- 100% Editable and Customizable
- Clear and Structured Layout
What Recent Changes Have Shaped Assertio’s Ownership Landscape?
Over the past few years, Assertio Holdings has undergone significant changes, particularly in its ownership and strategic direction. A key move in 2025 was the simplification of its corporate structure, including the transfer of all interests in Assertio Therapeutics to ATIH Industries, LLC. This strategic shift aimed to reduce legal exposure, especially concerning opioid-related litigation. As of May 12, 2025, neither Assertio Holdings nor its current subsidiaries are named defendants in any opioid-related litigation. This restructuring is part of a broader transformation strategy for 2025, which also includes investments in growth assets like Rolvedon and Sympazan, and the potential divestiture of declining or non-core assets. This is relevant for anyone researching Assertio ownership.
In terms of Assertio ownership trends, institutional investors continue to hold a significant stake. As of March 31, 2025, notable institutional shareholders included Nantahala Capital Management, LLC, Vanguard Group Inc., and BlackRock, Inc. Although there was some turnover, with 35 institutional investors adding shares in Q4 2024, while 69 decreased their positions. Insider trading activity, as of March 5, 2025, showed two purchases by insiders, including CEO Brendan P. O'Grady and Heather L. Mason, with no sales. The company's market capitalization was approximately $59.1 million as of June 12, 2025, reflecting a decrease of 35.02% in one year. Assertio's management anticipates 2025 to be a 'transformational year' with a focus on revenue growth initiatives for Rolvedon and Sympazan, and an active pursuit of strategic acquisitions. The company ended 2024 with $100.1 million in cash and investments and $40.0 million in convertible notes debt due September 2027. For more information on the target market, consider reading the article Target Market of Assertio.
The company's strategic focus on growth assets and potential acquisitions indicates a proactive approach to expanding its portfolio. The financial restructuring and simplification of the corporate structure are aimed at mitigating risks and improving operational efficiency. These developments are crucial for understanding the future trajectory of Assertio Pharmaceuticals and its impact on Assertio investors.
Ownership Structure
Assertio Holdings has undergone significant shifts, including transferring interests in Assertio Therapeutics to ATIH Industries, LLC.
Institutional Investors
Nantahala Capital Management, LLC, Vanguard Group Inc., and BlackRock, Inc. are among the largest institutional shareholders.
Financial Performance
Market capitalization was approximately $59.1 million as of June 12, 2025, and the company ended 2024 with $100.1 million in cash.
Strategic Initiatives
Focus on revenue growth for Rolvedon and Sympazan, and active pursuit of strategic acquisitions are key priorities for 2025.
Assertio Porter's Five Forces Analysis
- Covers All 5 Competitive Forces in Detail
- Structured for Consultants, Students, and Founders
- 100% Editable in Microsoft Word & Excel
- Instant Digital Download – Use Immediately
- Compatible with Mac & PC – Fully Unlocked
Related Blogs
- What are Mission Vision & Core Values of Assertio Company?
- What is Competitive Landscape of Assertio Company?
- What is Growth Strategy and Future Prospects of Assertio Company?
- How Does Assertio Company Work?
- What is Sales and Marketing Strategy of Assertio Company?
- What is Brief History of Assertio Company?
- What is Customer Demographics and Target Market of Assertio Company?
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.